Church & Dwight Co., Inc. — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the provided filing text does not give a separate fourth-quarter income statement or clear standalone Q4 results. Dollar amounts are in millions unless noted.
Business context
Church & Dwight develops and sells household, personal care and specialty products, including ARM & HAMMER, OXICLEAN, WATERPIK, THERABREATH and HERO. The business reports Consumer Domestic, Consumer International and Specialty Products Division (SPD); these represented approximately 78%, 17% and 5% of 2023 net sales, respectively. Seven “power brands” represented approximately 70% of net sales and profits.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Net sales | $5,867.9 (+9.2%) | $5,375.6 |
| Gross profit / margin | $2,588.5 / 44.1% | $2,250.0 / 41.9% |
| Operating income / margin | $1,057.4 / 18.0% | $597.8 / 11.1% |
| Net income | $755.6 | $413.9 |
| Diluted EPS | $3.05 | $1.68 |
| Cash from operations | $1,030.6 | $885.2 |
| Capital expenditures | $223.5 | $178.8 |
- Sales growth comprised 0.9% volume, 4.4% pricing/product mix and 3.9% acquired product lines, principally the 2022 HERO acquisition.
- Gross margin improved 220 basis points, reflecting pricing/mix, productivity, lower transportation costs and acquisition benefits, partly offset by higher manufacturing, labor and commodity costs.
- 2022 included a $411.0 non-cash impairment of FINISHING TOUCH FLAWLESS intangible assets. Excluding that charge, 2023 operating margin decreased 70 basis points, as higher gross margin was offset by increased marketing and SG&A costs. The reported EPS comparison is likewise affected by the impairment.
- Marketing expense was $641.3, or 10.9% of sales, versus $535.2, or 10.0%, in 2022. Interest expense rose to $110.9 from $89.6. The effective tax rate was 21.9%, compared with 20.9%.
- Year-end cash and cash equivalents were $344.5. Debt was approximately $2,406.0 net of issuance costs; about 92% was fixed-rate debt, at a 4.1% weighted-average rate. The company reported approximately $1,495.0 available through its revolving credit facility and commercial paper program. The $200.0 term loan due December 2024 was partly repaid in January 2024 ($100.0).
- Operating, investing and financing cash flows were $1,030.6, $(234.3) and $(725.6), respectively. Financing cash use included $300.1 of share repurchases and $266.5 of dividends.
Material changes versus 2022
- Consumer Domestic sales rose 10.7% to $4,571.2, supported by HERO acquisition contributions, pricing/mix and selected brand growth. Consumer International sales increased 8.9% to $975.7.
- SPD sales fell 7.9% to $321.0, mainly because of competitive imports in the domestic dairy market; SPD income before tax declined to $21.2 from $44.9.
- Household products revenue increased to $2,484.1 from $2,272.0; personal care products revenue increased to $2,087.1 from $1,859.0.
- Cash from operations increased $145.4, principally from improved working capital and higher cash earnings. Cash conversion cycle rose to 27 days from 19, partly due to lower days payable outstanding.
Outlook, management commentary and risks
- Management expects operating cash flow and borrowing capacity to cover debt service, dividends, repurchases as implemented, and planned 2024 capital spending of approximately $180.0, mainly to expand laundry, litter and vitamin capacity. The filing provides no clear numeric 2024 sales or EPS guidance.
- Management plans to exit the MEGALAC dairy supplement portion of Animal Nutrition in Q1 2024 amid renewed foreign competition. A 4% quarterly dividend increase was declared in January 2024, to $0.28375 per share.
- Management cited pressure on discretionary WATERPIK and FLAWLESS demand, increased value-brand competition in water flossers, and vitamin competition and lost shelf space. It is responding with promotional and marketing spending, product development and lower-cost alternatives.
- WATERPIK’s estimated fair value was only 109% of carrying value at the October 2023 impairment test; continued deterioration could trigger impairment. VITAFUSION/L’IL CRITTERS also had reduced valuation headroom. Deloitte identified valuation of the WATERPIK and vitamin trade names as a critical audit matter. No impairment of these indefinite-lived trade names was recorded in 2023.
- Other risks include intense competition and private labels, customer concentration (Walmart represented 23% of sales), raw-material and labor cost volatility, supply and transport disruptions, tariffs and currency movements, regulation and product liability, cybersecurity, and litigation or environmental contingencies. The company reported no relevant legal proceedings to disclose for the period, while noting ordinary-course matters with uncertain outcomes.
Important facts for investors to verify
- Whether underlying volume and margins can hold up as pricing growth moderates and marketing spending increases.
- Progress in WATERPIK and vitamin brand recovery, and the assumptions behind their impairment valuations.
- Effects of the MEGALAC exit and continued foreign competition on SPD results.
- Debt repayment and refinancing needs, particularly the remaining term loan due December 2024, alongside planned capital spending and shareholder returns.
- Customer concentration and exposure to Walmart, private-label competition and retailer bargaining power.